Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haiyan, Xiang, Bing, Song, Yuqin, Zhang, Huilai, Zhao, Weili, Zou, Dehui, Lv, Fangfang, Guo, Wei, Liu, Aichun, Li, Caixia, Tan, Ziwen, Liu, Yang, Fu, Lina, Guo, Haiyi, Novotny, William, Huang, Jane, Li, Yufu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941452/
https://www.ncbi.nlm.nih.gov/pubmed/34638136
http://dx.doi.org/10.1182/bloodadvances.2020003698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941452/
https://www.ncbi.nlm.nih.gov/pubmed/34638136
http://dx.doi.org/10.1182/bloodadvances.2020003698

Ejemplares similares